Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...

Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

About BAT2506 (golimumab) BAT2506 is a proposed biosimilar to Simponi ® which is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- α), a pro-inflammatory molecule.

Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today ...

BAT2506 is a proposed biosimilar to Simponi® which is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- α), a pro-inflammatory molecule. Binding of golimumab to TNF ...

For quantitative flow cytometry, cells were stained with AF488-conjugated mouse antihuman TROP2 antibody (clone 77220, R&D Systems) or an isotype control antibody. The number of binding sites of the ...

Immunotherapy. 2012;4(11):1167-1179. Up to half the patients on anti-TNF-α therapies have inadequate responses. Substantial inter- and even intra-individual variations in the pharmacokinetics of ...

A thyroglobulin antibody (TgAb) test looks for certain antibodies that attack the thyroid. The presence of TbAb in high levels may indicate that someone has an autoimmune condition. To conduct a ...

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a condition of the nervous system that can be managed with lifestyle modifications or medications, depending on your individual needs.